Regeneron’s Ordspono (Odronextamab) Receives the EC’s Approval to Treat R/R Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Shots:
- The EC has approved Ordspono for treating r/r FL or r/r DLBCL in patients who have progressed after ≥2L of systemic therapy
- Approval was supported by Ordspono’s P-I (ELM-1; n=60) trial in patients with CD20+ B-cell malignancies, incl. those who progressed post CAR-T therapy & P-II (ELM-2; n=128) trial for 5 B-cell lymphoma subtypes such as DLBCL, FL, mantle cell lymphoma, marginal zone lymphoma
- R/R FL patients (ELM-2) had an ORR of 80% & CR in 73% (mDoR: 25mos.); r/r DLBCL patients naïve to CAR T therapy (ELM-2) had an ORR of 52% & CR in 31% (mDoR: 18mos.); r/r DLBCL patients who progressed post CAR-T therapy (ELM-1) had an ORR of 48% & CR in 32% (mDoR: 15mos.
Ref: Regeneron | Image: Regeneron
Related News:- Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
